hours with DME, fixed and stained for microtubules (green), centrosome--associated pericentrin (red) and chromatin (DAPI, blue). Size bar 10 µm. B. H--RasV12 activation reduces apoptosis caused by DME treatment. Induced (Ras) or control (Cntr) ERRAS cells were incubated with DME for 17 hours before detecting apoptotic cells with NucView 488 caspase 3 substrate by flow cytometry. Cell debris were excluded from analysis. C. As in B, but only phospho--H3--positive cells in the DME--treated population were analysed. D. Activated H--RasV12 provides cells with a selective advantage in the presence of DME. IMR90 cells co--expressing inducible H--RasV12 and GFP (red or blue indicate a proportion of induced or control cells respectively) were mixed with equal number of GFP--negative parental cells (proportion indicated by grey). The proportion of GFP--positive cells in the mixed cultures was measured by flow cytometry immediately after mixing and for three consecutive days. In the presence of both 4OHT and DME, H--RasV12 expressing cells exhibited a selective advantage over parental H--RasV12 negative cells (row 1). However, when H--RasV12 was not induced (row 2), DME did not alter the ratio between the two cell types. In the absence of DME, both induced (row 3) and control (row 4) ERRAS cells had a slight growth disadvantage and were eventually outgrown by the parental IMR90 cells. E. Treatment of H--RasV12 expressing cells with DME leads to multinucleation. Induced ERRAS cells were treated with DME as in Fig   6A , and two days after drug removal (7 days of H--RasV12 induction) surviving cells were fixed, stained with DAPI and imaged using Operetta scanner. Insert shows a magnified fragment. Gold mounting media (Invitogen).
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Imaging and file processing
Immunofluorescently stained fixed cells were imaged either with epi--fluorescent Nikon Eclipse 80i microscope equipped with Hamamatsu ORCA--ER camera and 
Measuring duration of mitosis/mitotic arrest and frequency of mitotic slippage
Mitotically arrested cells in time--lapse images of DME--treated populations or untreated mitoses were tracked using Image J. The duration of mitotic arrest was calculated from the time of cell rounding (with signs of chromatin condensation when visible) to either cell death (at the onset of extensive terminal blebbing) or slippage (cell flattening). For each experimental point, we scored all identifiable mitotic cells in 3--4 time--lapse sequences from the same well. The data were further analysed in Microscoft Excel.
Immunoblotting. Adherent cells were washed twice with PBS and boiled in 2xSDS lysis buffer containing 4% SDS, 12.5 mM TrisHCl pH 6.8 and 20% glycerol. Harmony software. When required (eg for Fig S2E and Fig S4C) , individual images were exported. We routinely seeded 8 wells per sample, of which one well was not pulsed with EdU and served as negative control.
PCR and qPCR.
Primers:
assay target sequence PCR MCL1L, MCL1S 5'--ATCTCTCGGTACCTTCGGGAGC --3'
Total RNA was extracted using RNeasy plus kit (Qiagen), followed by DNase I treatment. cDNA was produced using oligo--dT primers. Semi--quantitative PCR was performed with indicated amount of cDNA, using Recombinant Taq (Filler et al., 2007) . Mice received the total of three 100 µl intaperitoneal injections of 0.5 mg/ml SB--743921 (Selleckchem) in 2% Cremophor, 98% sterile water pH 5.0 (final dose 2.5 mg/kg per injection) or equal volume of vehicle during the first week of TPA treatment, 6 hours after TPA application each.
In a pilot study, 7 weeks old FVB or C57Bl6 female mice received 2 weekly courses of 3 x 100 µl intaperitoneal injections of 0.5 mg/ml SB--743921 (Selleckchem) in 2% Cremophor, 98% sterile water pH 5.0 (final dose 2.5 mg/kg per injection) or equal volume of vehicle, and their health was monitored for another two weeks. Two mice per strain/treatment were sacrificed 6 hours after third injection, and the effectiveness of drugs was assessed by quantifying mitotic and apoptotic indices in Haematoxylin & Eosin stained paraffin sections of intestinal crypts.
As a positive control for p16 activation, we used p16 Luc/wt mouse 10--17 days after cutaneous wounding. The 5 mm diameter wound was created by dorsal skin incision of an anesthetized mouse. Subcutaneous injection of rimadyl prior the biopsy and oral rimadyl for 3 days after the biopsy was used for analgesia.
All mice were maintained in pathogen--free facilities proactive in environmental enrichment. All animal work was carried out according to UK Home Office regulations, in line with the EU directive 2010 and approved by ethical review (University of Glasgow).
In vivo luciferase detection.
Mice subcutaneously injected with 100 µl of 30 mg/ml RediJect D--Luciferin Bioluminescent Substrate (Perkin Elmer) were anesthetized with isoflurane and, 5 min after luciferin injection, imaged using IVIS Spectrum system (Caliper Life Sciences, Perkin Elmer). The radiance within equally sized dorsal regions (the areas subjected to the DMBA and TPA applications) was calculated using Living
Image software (Caliper Life Sciences), before subtracting the background, derived by identical measurements of similarly treated p16 wt/wt Albino C57Bl6 mouse (without a transgene).
Histopathology, immunohistochemistry and tissue immunofluorescence
4 µm sections cut from formalin fixed paraffin embedded blocks were baked onto poly--lysine slides for 60 minutes at 60°C. Sections were stained with
